Copyright
©The Author(s) 2016.
World J Diabetes. Nov 15, 2016; 7(19): 534-546
Published online Nov 15, 2016. doi: 10.4239/wjd.v7.i19.534
Published online Nov 15, 2016. doi: 10.4239/wjd.v7.i19.534
Figure 10 Ultrastructural changes in the hepatocytes of placebo-treated db/db mice.
A: Fatty degeneration, numerous compartments of mito-ER-complexes, free ribosomes and polysomes, pronounced hyperplasia of the microvilli on the vascular poles and lateral sites of parenchymal cells, enlarged Disse spaces; the arrows indicate the extension between the lateral surfaces of adjacent hepatocytes; B: Hyperplasia of microvilli on the lateral parts of the hepatocytes and transport of lipid inclusions (arrow) into spaces between hepatocytes; C: The transport of lipid inclusions into Disse spaces (arrows), transport vacuoles into the cytoplasm of endothelial sinusoidal cells; D: Active Golgi complexes, autophagosomes with dark content and ribosomes in peribiliary areas of hepatocytes; the arrow shows the transport of lipid inclusions into the gap between hepatocytes; E: Structural complexes of lipid inclusions with mitochondria. ap: Autophagosome; g: Glycogen granules; D: The Disse space; bc: Bile capillary; GC: Golgi complex; L: Lipid inclusion; m: Mitochondria; s: Lumen of the sinusoid; e: Erythrocyte; N: The nucleus.
- Citation: Michurina SV, Ishenko IJ, Klimontov VV, Archipov SA, Myakina NE, Cherepanova MA, Zavjalov EL, Koncevaya GV, Konenkov VI. Linagliptin alleviates fatty liver disease in diabetic db/db mice. World J Diabetes 2016; 7(19): 534-546
- URL: https://www.wjgnet.com/1948-9358/full/v7/i19/534.htm
- DOI: https://dx.doi.org/10.4239/wjd.v7.i19.534